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Objective: We sought to determine the prevalence and severity of anxiety and depression 
among patients with Philadelphia-negative myeloproliferative neoplasms (MPNs) and respec-
tive associations of anxiety and depression with demographic and lifestyle factors, comorbidity 
burden, duration of MPN disease, financial difficulties, and health-related quality of life (QoL).
Methods: This study used data from a nationwide, population-based, cross-sectional survey 
of health-related QoL in MPN patients in Denmark called the MPNhealthSurvey. Individuals 
with a diagnosis of MPN in the National Patient Register were invited. The Hospital Anxiety 
and Depression Scale was used to assess the prevalence and severity of anxiety and depression. 
The associations of anxiety and depression with age, sex, education, body mass index (BMI), 
smoking, alcohol intake, physical activity, comorbidity burden, duration of MPN disease, 
financial difficulties, symptom burden, sexual problems, fatigue, functioning, and global health/
QoL were examined.
Results: In total, 2,029 patients completed the Hospital Anxiety and Depression Scale. The 
prevalence of anxiety, depression, and both was 21%, 12%, and 8%, respectively. Many partici-
pants who reported anxiety or depression exhibited mild symptoms. Middle-aged and elderly 
participants had lower odds of experiencing anxiety and depression when compared to younger 
participants, and females had higher odds of anxiety compared to males. Participants with higher 
education had lower odds of anxiety compared to those with lower education. Current smokers 
and ex-smokers had higher odds of anxiety and depression compared to those who had never 
smoked, and sedentary participants and participants with a lower level of physical activity had 
higher odds of anxiety and depression compared to participants who performed hard training 
several times a week. Higher comorbidity burden increased the odds of depression, and greater 
financial difficulties increased the odds of anxiety and depression. Higher total symptom bur-
den and fatigue burden and higher level of sexual problems increased the odds of anxiety and 
depression. Finally, lower functional level and global health/quality of life increased the odds 
of anxiety and depression. BMI, alcohol intake, comorbidity burden, and duration of disease 
were not substantially associated with anxiety, whereas sex, educational level, and duration of 
MPN disease were not substantially associated with depression.
Conclusion: There may be an unmet need in handling psychological distress in MPN patients. 
Future research might explore the utility of screening for psychological distress and the effec-
tiveness of lifestyle interventions, rehabilitation, and MPN-symptom reduction in preventing 
and treating psychological distress.
Keywords: myeloproliferative neoplasm, anxiety, depression, health-related quality of life, 
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Introduction
The classical Philadelphia-negative myeloproliferative neo-
plasms (MPNs) include three diseases: essential thrombocythe-
mia (ET), polycythemia vera (PV), and myelofibrosis (MF). In 
addition, some Philadelphia-negative MPNs are unclassifiable 
(MPN-U).1,2 Bone-marrow transplantation can cure MPN, but 
very few patients are eligible for this treatment.3 As such, MPNs 
are chronic diseases for the vast majority of patients. However, 
MPNs may develop into acute myeloid leukemia.1
For many MPN patients, living with one of these diseases 
entails burdensome symptoms, sexual concerns, financial dif-
ficulties, limited functioning in everyday life, and a reduced 
life span.4–11 Struggling with health issues in everyday life 
and the prospect of possible symptom burden worsening, as 
well as reduced life span, may be psychologically challenging 
and cause psychological distress (here defined as symptoms 
of anxiety and/or depression). 
Understanding the prevalence of anxiety and depression 
in MPN patients is crucial in determining how attentive 
health-care professionals must be in monitoring for the signs 
of these conditions. Moreover, knowledge of factors associ-
ated with anxiety and depression in MPN patients can help 
health-care professionals identify who might be particularly 
vulnerable patients, prevent development of anxiety and 
depression, and elucidate explanations for the presence of 
psychological distress in individual cases. However, to our 
knowledge, only two previous studies have explored anxiety 
and depression in MPN patients, both of them in patients with 
different disease duration. In an American single-center study 
from 2015, the prevalence of anxiety and depression was 31% 
and 13%, respectively, measured by the Hospital Anxiety and 
Depression Scale (HADS), in an MPN population consisting 
of 117 ET, PV, and MF patients.12 In an international survey 
from 2014, the prevalence of depression was 23%, measured 
by the Patient Health Questionnaire 2, in 1,676 ET, PV, and 
MF patients.6 In the latter study, associations were found 
between depression and younger age, lower educational level, 
high fatigue and total symptom burden, and impaired qual-
ity of life (QoL), while no association was found between 
depression and MPN subtype.
Given the scantiness of research on this topic, we saw 
a need for a robust survey investigating the prevalence and 
severity of anxiety and depression and factors associated 
with these conditions in a large population of MPN patients. 
The results from such a survey could help guide health-care 
professionals on how to detect, prevent, and treat anxiety 
and depression in these patients. In Denmark, MPN patients 
attend public hospitals. The health-care system is financed by 
taxes, and covers the treatment expenses for all hematological 
diseases. Diagnoses are recorded at hospitals and forwarded 
to the National Patient Register (NPR).13,14 Furthermore, 
every resident in Denmark has a Civil Personal Register 
(CPR) number, which is linked to personal and demographic 
information in the CPR.13,15 As a result of these practices, we 
were able to undertake a nationwide, population-based survey 
of anxiety and depression and factors associated with these 
conditions in MPN patients who had equal, cost-free access 
to the best available treatment for their hematological disease.
The present study aims to show the prevalence and 
severity of anxiety and depression in Philadelphia-nega-
tive MPN patients, based on the results of a nationwide, 
population-based, cross-sectional survey on health-related 
QoL conducted in Denmark called the MPNhealthSurvey. 
Furthermore, we sought to determine potential associations 
of anxiety and depression with demographic and lifestyle 
factors, comorbidity burden, duration of disease, financial 
difficulties, and health-related QoL in these participants.
Methods
The methods of the MPNhealthSurvey have been described 
in detail in a previously published article.16 Here, we describe 
only the methods relevant to the investigation of anxiety and 
depression.
Participants
We identified individuals diagnosed with ET, PV, MF, or 
MPN-U based on the International Classification of Diseases 
(ICD) codes recorded in the NPR in Denmark between 1977 
(when the NPR was created) and March 31, 2013, and who 
were alive on September 4, 2013, when the survey population 
was formed. The following MPN ICD-diagnosis codes were 
used: ICD8 287.29 and ICD10 D47.3 for ET, ICD8 208.99 
and ICD10 D45 for PV, ICD8 209 and ICD10 D47.4 for MF, 
and ICD10 D47.1 for chronic myeloproliferative disease. 
The diagnosis of MPN had to be recorded at least once at a 
department of hematology or internal medicine that handles 
or had previously handled MPN patients. The ICD-diagnosis 
codes for inpatients have been registered in the NPR since 
its creation in 1977, while those for outpatients have been 
recorded from 1995.14
All individuals who met the aforementioned inclusion 
criteria were invited to participate in the survey, except those 
who were registered as protected from being contacted to 
participate in research or from having to disclose their address 
information. Patients’ addresses were found in the CPR.15 On 
September 11, 2013, a survey booklet, an envelope with a 
stamp, a code for logging into the online survey, and a cover 
letter were sent to all MPN patients who met the inclusion 
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criteria. Individuals were asked to complete and return 
the survey booklet or complete the same survey online. A 
reminder letter was dispatched to invited patients who had not 
responded to the survey before October 25. The survey period 
ended on December 31, 2013. All Philadelphia-negative 
participants in the MPNhealthSurvey who had not developed 
acute myeloid leukemia or undergone bone-marrow trans-
plantation and who had completed the HADS questionnaire 
constitutes the population under study here.
Participant characteristics
Information on age and sex was retrieved from the CPR. Partic-
ipants themselves provided information about their educational 
level and lifestyle, including smoking habits, weekly alcohol 
intake, and physical activity.17–20 Participants were also asked to 
write down height and weight for the calculation of their body 
mass index (BMI). Comorbid diagnoses included all diagno-
ses registered in the NPR in the 5 years before September 4, 
2013 and that are included in the Charlson Comorbidity Index 
(CCI).21 MPN diagnoses were excluded when evaluating the 
comorbidity burden. The duration of disease was established 
as the time span between the date of the first registration of an 
MPN disease in the NPR and September 4, 2013.
Anxiety and depression assessment
Participants completed the HADS.22,23 The HADS is a symp-
tom-specific questionnaire originally developed to detect and 
examine the severity of symptoms of anxiety and depression 
in hospital outpatients; however, subsequent use has shown 
it to be a reliable questionnaire for measuring anxiety and 
depression in cancer settings.24 It contains 14 items, with 
separate scales for anxiety and depression. Scores range from 
0 to 21. A score <8 is interpreted as no anxiety/depression, 
8–10 as mild anxiety/depression, 11–14 as moderate anxiety/
depression, and 15–21 as severe anxiety/depression.23
Prevalence and severity of anxiety and 
depression
The prevalence of anxiety and depression was assessed for all 
participants who completed the HADS in the MPNhealthSur-
vey and for each subgroup of participants by MPN subtype. 
Furthermore, the prevalence of both anxiety and depression 
was assessed for both the total population and the MPN sub-
groups. Differences in prevalence between MPN subgroups 
were determined. The presence and severity of anxiety and 
depression, respectively, were explored using the aforemen-
tioned divisions of the two conditions into not present, mild, 
moderate, and severe as prescribed in the HADS manual.23
Factors associated with anxiety and 
depression
Examination of factors potentially associated with anxiety 
and depression was done on the total study population. To 
examine these associations, we used a HADS cutoff score 
of 8 to indicate anxiety and depression. Age, sex, education, 
lifestyle factors, comorbidity burden, duration of disease, 
financial difficulties, symptom burden, sexual problems, 
fatigue, functioning, and global health/QoL were investigated 
for potential associations with anxiety and depression. The 
presence of typical MPN symptoms was measured by the dis-
ease-specific MPN questionnaire called the MPN Symptom 
Assessment Form (MPN-SAF).9 This tool was developed for 
use in combination with the Brief Fatigue Inventory, which 
measures fatigue related to cancer and the impact of this 
fatigue on daily living.25 A total symptom score (TSS) was 
calculated based on certain prevalent symptoms measured by 
the MPN-SAF and Brief Fatigue Inventory, according to the 
MPN-SAF TSS manual.26 Specifically, the MPN-SAF TSS 
was calculated from the following symptoms: worst level 
of fatigue during the last 24 hours, early satiety, abdominal 
discomfort, inactivity, concentration problems, night sweats, 
itching, bone pain, fever, and weight loss. The MPN-SAF TSS 
ranges from 0 to 100. A high score indicates a high symptom 
burden. Sexual problems were investigated using a single 
item in the MPN-SAF. This item score ranges from 0 to 10. A 
high number indicates a high level of sexual problems. Finan-
cial difficulties, fatigue, functioning, and global health/QoL 
were measured using the European Organisation for Research 
and Treatment of Cancer Quality of Life Questionnaire Core-
30 (EORTC QLQ-C30):27 functioning was subdivided into 
physical, role, cognitive, emotional, and social functioning 
according to the questionnaire manual. EORTC QLQ-C30 
scores range from 0 to 100. A high score on the fatigue scale 
indicates a high fatigue burden. A high score on a function-
ing scale and the global health/QoL scale indicates better 
functioning and global health/QoL, respectively. Participants’ 
symptom burden, sexual problems, fatigue, functioning, and 
global health/QoL scores are presented as quartiles.28 Social 
functioning score is divided into three levels.
Confounders
Age, sex, and comorbidity were considered important 
confounders for anxiety and depression. Therefore, these 
were adjusted for when examining the associations of dif-
ferent factors with anxiety and depression in the MPN study 
population. MPN diagnoses were excluded when calculating 
the comorbidity burden, because in this study we wanted to 
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adjust for comorbid diseases when examining the factors 
associated with anxiety and depression related to the MPN.
Statistics
Frequency distributions and percentages for the different 
demographic and lifestyle factors, CCI, and disease duration 
were calculated for the total study population and for each 
MPN subgroup. In analyses of factors associated with anxiety 
and depression, the effects of age, sex, and CCI on anxiety 
and depression were tested in a multivariate model including 
all three covariates simultaneously, while the effects of the 
other factors on anxiety and depression were tested using 
separate logistic regression models, each adjusted for age, 
sex, and CCI. In analyses of the associations of anxiety and 
depression with symptom burden, sexual problems, fatigue, 
functioning, and global health/QoL, 25th quartile, median, 
and 75th quartile were used to divide the scores into different 
levels. Social functioning score was divided into three levels, 
because half the population had a score of 100. Odds ratios 
tend to overestimate proportion-ratios when events are rather 
frequent like anxiety and depression in this study. We there-
fore tried to carry out log-binomial regressions to estimate 
relative risks in place of odds ratios. However, the procedure 
for estimating relative risks in a log-binomial regression is 
more prone to numerical instability or lack of convergence, 
and we found that only in about half of our models we were 
able to get estimates and associated hessian matrices. Thus, 
while it might be preferable to use relative risks in lieu of odds 
ratios, we kept the odds ratios for consistency. R software 
3.4.3 was employed for all statistical analyses.
Ethics
The Danish Data Protection Agency approved the survey (SJ-
RO-02). Approval from the Committee on Health Research 
Ethics was not obligatory, and informed consent from the 
participants was not required (Committee Act section 14.2; 
National Committee on Health Research Ethics [Denmark] 
guidelines).29
Results
Response rate and participant 
characteristics
The MPNhealthSurvey had a response rate of 60% of the total 
population of patients with Philadelphia-negative MPN in 
Denmark registered in the NPR and eligible for participation. 
Of these participants, 2,029 (95%) completed the HADS, 
including 695 ET, 870 PV, 67 MF, and 397 MPN-U patients 
(Table 1). Participants’ mean age was 68 years. More females 
than males completed the questionnaire (56% females, 44% 
males), and more participants were middle-aged than young 
or elderly (8% females and 7% males <50 years, 58% females 
and 60% males 50–75 years, and 34% females and 33% males 
>75 years). More participants had completed upper secondary/
vocational school than either basic school or higher education 
(19% had completed basic school, 39% upper secondary/
vocational school, 20% higher education, and 22% had not 
completed the answers to educational level). Many participants 
had a relatively healthy lifestyle. Half the participants had no 
or low comorbidity burden (50% had a CCI score of 0, 37% 
1–2, and 13% ≥3). The majority of participants were not newly 
diagnosed with MPN: of note, patients diagnosed within half a 
year prior to the survey were not invited to participate (7% had 
been diagnosed for <1 year, 36% 1–4 years, and 57% ≥5 years).
Prevalence and severity of anxiety and 
depression
Anxiety was more prevalent than was depression (21% 
of the total population had anxiety, 12% depression, and 
8% both; Table 2). The prevalence of anxiety was highest 
among participants with ET and lowest among those with 
MF (23% ET, 21% MPN-U, 19% PV, and 15% of MF par-
ticipants reported anxiety). The prevalence of depression 
was highest among participants with ET and MPN-U and 
lowest among MF participants (13% ET, 13% MPN-U, 12% 
PV, and 6% MF participants reported depression). Most 
participants with anxiety reported mild anxiety (13% mild, 
7% moderate, and 1% severe anxiety). A similar pattern 
was seen for depression (8% mild, 3% moderate, and 1% 
severe depression).
Factors associated with anxiety
Middle-aged and elderly participants had lower odds of anxi-
ety compared to younger patients, while females had higher 
odds of anxiety compared to males (Table 3). Participants 
with higher education had lower odds of anxiety compared to 
those with lower education. Current smokers and ex-smokers 
had higher odds of anxiety compared to participants who 
had never smoked. Participants who were sedentary or less 
physically active had increased odds of anxiety compared to 
participants who reported performing hard training several 
times a week. Greater financial difficulties were associated 
with higher odds of anxiety. Higher total symptom burden and 
fatigue burden, and higher level of sexual problems, increased 
the odds of anxiety. Indeed, high symptom burden and high 
fatigue burden were strongly associated with anxiety. Gener-
ally, lower levels of functioning and lower global health/QoL 
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Table 1 Participant characteristics
ET + PV +  
MF + MPN-U
ET PV MF MPN-U
Total (n) 2,029 695 870 67 397
Age, years, mean (SD) 68.90 (12.37) 67.24 (13.30) 69.56 (11.52) 71.32 (12.74) 69.96 (12.15)
Sex, n (%)
Female
Male
1,146 (56)
883 (44)
441 (63)
254 (37)
435 (50)
435 (50)
34 (51)
33 (49)
236 (59)
161 (41)
Female, n (%)
<50
50–75
>75
95 (8)
668 (58)
383 (34)
48 (11)
254 (58)
139 (31)
24 (6)
271 (62)
140 (32)
2 (6)
16 (47)
16 (47)
21 (9)
127 (54)
88 (37)
Male, n (%)
<50
50–75
>75
64 (7)
528 (60)
291 (33)
26 (10)
156 (62)
72 (28)
29 (7)
257 (59)
149 (34)
2 (6)
20 (61)
11 (33)
7 (4)
95 (59)
59 (37)
Education, n (%)
Basic school
Upper secondary/vocational school
Higher education
Missing
383 (19)
796 (39)
412 (20)
438 (22)
138 (20)
254 (37)
142 (20)
161 (23)
158 (18)
340 (39)
175 (20)
197 (23)
5 (8)
33 (49)
18 (27)
11 (16)
82 (21)
169 (43)
77 (19)
69 (17)
BMI, n (%)
<18.5
≤18.5–<25.0
≤25.0–<30.0
≥30
Missing
52 (3)
1,034 (51)
615 (30)
261 (13)
67 (3)
14 (2)
370 (53)
208 (30)
78 (11)
25 (4)
23 (3)
431 (49)
270 (31)
119 (14)
27 (3)
2 (3)
33 (49)
20 (30)
10 (15)
2 (3)
13 (3)
200 (50)
117 (30)
54 (14)
13 (3)
Smoking, n (%)
Yes
Ex-smoker
No
Missing
360 (18)
895 (44)
722 (36)
52 (2)
125 (18)
295 (42)
262 (38)
13 (2)
149 (17)
398 (46)
298 (34)
25 (3)
9 (13)
30 (45)
25 (37)
3 (5)
77 (19)
172 (43)
137 (35)
11 (3)
Alcohol, units, n (%)
≤7
≤8–≤14
≤15–≤21
≤22
Missing
1,379 (68)
353 (17)
148 (7)
141 (7)
8 (1)
464 (67)
136 (19)
53 (8)
37 (5)
5 (1)
575 (66)
155 (18)
65 (7)
73 (8)
2 (1)
44 (66)
12 (18)
4 (6)
6 (9)
1 (1)
296 (74)
50 (13)
26 (7)
25 (6)
0
Physical activity, n (%)
Hard training and competitive sports several times a week
Training, heavy garden work, or similar ≥4 times a week
Walking, cycling, light garden work, or similar ≥4 times a week
Reading, watching tv, or other sedentary work
Missing
106 (5)
403 (20)
946 (47)
472 (23)
102 (5)
51 (7)
150 (22)
326 (47)
142 (20)
26 (4)
37 (4)
177 (20)
409 (47)
200 (23)
47 (6)
2 (3)
12 (18)
22 (33)
24 (36)
7 (10)
16 (4)
64 (16)
189 (48)
106 (27)
22 (5)
Comorbidity, CCI score
Mean (SD)
0, n (%)
1–2, n (%)
≥3, n (%)
1.10 (1.67)
1,016 (50)
742 (37)
271 (13)
0.94 (1.54)
379 (54)
241 (35)
75 (11)
1.16 (1.68)
416 (48)
321 (37)
133 (15)
1.39 (2.17)
35 (52)
18 (27)
14 (21)
1.17 (1.77)
186 (47)
162 (41)
49 (12)
Duration of disease, n (%)
<1 year
1–4 years
≥5 years
150 (7)
729 (36)
1,150 (57)
48 (7)
250 (36)
397 (57)
45 (5)
274 (32)
551 (63)
26 (39)
28 (42)
13 (19)
31 (8)
177 (44)
189 (48)
Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; ET, essential thrombocythemia; MF, myelofibrosis; MPN-U, myeloproliferative neoplasm – 
unclassifiable; PV, polycythemia vera.
were associated with higher odds of anxiety. BMI, alcohol 
intake, comorbidity burden, and duration of disease were not 
substantially associated with anxiety.
Factors associated with depression
Middle-aged and elderly participants had lower odds of 
depression compared to younger patients (Table 4). Lifestyle 
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factors were associated with depression: current smokers 
had higher odds of depression compared to participants 
who had never smoked, and a similar tendency was seen 
for ex-smokers; sedentary participants had higher odds of 
depression compared to those who were physically active; 
excessive alcohol intake (≥22 units per week) was associated 
with higher odds of depression compared to a lower intake, 
but moderate to high alcohol intake (8–21 units per week) 
was associated with lower odds of depression compared 
to low alcohol intake (≤7 units per week). BMI was not 
significantly associated with depression. Higher comorbid-
ity burden increased the odds of depression, as did greater 
financial difficulties. Higher total symptom burden, higher 
level of sexual problems, and higher fatigue burden increased 
the odds of depression compared to lower symptom burden, 
lower level of sexual problems, and lower fatigue burden. 
Of these, high symptom burden and high fatigue burden had 
particularly strong associations with depression. Lower levels 
of functioning in general were associated with higher odds 
of depression compared to higher levels of functioning: the 
lower the functioning level, the higher the odds of depression. 
Low global health/QoL was remarkably strongly associated 
with depression compared to high global health/QoL. Sex, 
educational level, and duration of MPN disease were not 
substantially associated with depression.
Discussion
In this nationwide, population-based, cross-sectional survey, 
2,029 participants with Philadelphia-negative MPNs com-
pleted the HADS, and self-reported prevalence of anxiety 
and depression was 21% and 12%, respectively. Mild forms 
Table 2 Prevalence and severity of anxiety and depression
HADS Total, n=2,029 ET, n=695 PV, n=870 MF, n=67 MPN-U, n=397
Anxiety, n (%)
Not present (score 0–7)
Present (score 8–21)
Mild (score 8–10)
Moderate (score 11–14)
Severe (score 15–21)
1,603 (79)
426 (21)
264 (13)
134 (7)
28 (1)
533 (77)
162 (23)
108 (16)
44 (6)
10 (1)
701 (81)
169 (19)
92 (11)
65 (7)
12 (1)
57 (85)
10 (15)
9 (13)
0
1 (2)
312 (79)
85 (21)
55 (14)
25 (6)
5 (1)
Depression, n (%)
Not present (score 0–7)
Present (score 8–21)
Mild (score 8-10)
Moderate (score 11–14)
Severe (score 15–21)
1,781 (88)
248 (12)
164 (8)
67 (3)
17 (1)
606 (87)
89 (13)
69 (10)
15 (2)
5 (1)
765 (88)
105 (12)
68 (8)
29 (3)
8 (1)
63 (94)
4 (6)
2 (3)
2 (3)
0
347 (87)
50 (13)
25 (7)
21 (5)
4 (1)
Both anxiety and depression, n (%)
Not present (score 0–7)
Present (score 8–21)
1,863 (92)
166 (8)
634 (91)
61 (9)
798 (92)
72 (8)
66 (99)
1 (1)
365 (92)
32 (8)
Abbreviations: ET, essential thrombocythemia; HADS, Hospital Anxiety and Depression Scale; MF, myelofibrosis; MPN-U, myeloproliferative neoplasm – unclassifiable; 
PV, polycythemia vera.
of these conditions were far more prevalent than moderate 
or severe forms. When prevalence by MPN subgroup was 
compared, ET participants reported the highest and MF par-
ticipants the lowest prevalence of anxiety, whereas ET and 
MPN-U participants reported the highest and MF participants 
the lowest prevalence of depression. However, differences 
between the MPN subgroups were minor. Middle-aged and 
elderly participants had lower odds of anxiety and depression 
than younger participants. Female sex was associated with 
higher odds of anxiety compared to male sex. Participants 
with higher education had lower odds of anxiety compared to 
those with lower education. Current smokers and ex-smokers 
had higher odds of anxiety and depression compared to 
those who never smoked, participants who were sedentary 
or less physically active had increased odds of anxiety and 
depression, and excessive alcohol intake was associated 
with higher odds of depression, whereas a moderate to high 
alcohol intake was actually associated with lower odds of 
depression. Higher comorbidity burden was associated with 
higher odds of depression, and greater financial difficulties 
increased the odds of anxiety and depression. Higher total 
symptom burden, higher level of sexual problems, and higher 
fatigue burden were associated with higher odds of anxiety 
and depression. Notably, high symptom burden and fatigue 
burden were very strongly associated with depression. Gener-
ally, lower level of functioning and lower global health/QoL 
were associated with higher odds of anxiety and depression. 
BMI, alcohol intake, comorbidity burden, and duration of dis-
ease were not substantially associated with anxiety, whereas 
sex, educational level, and duration of MPN disease were not 
substantially associated with depression.
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Table 3 Factors associated with anxiety
OR (95% CI)*
Demographics
Age, years
<50
50–75
>75
Reference
0.37 (0.26–0.53)
0.31 (0.21–0.46)
Sex
Male
Female
Reference
1.62 (1.29–2.03)
Education
Basic school
Upper secondary/vocational school
Higher education
Reference
0.62 (0.46–0.83)
0.70 (0.50–0.98)
Lifestyle
BMI
<18.5
≤18.5–<25.0
≤25.0–<30.0
≥30.0
Reference
1.15 (0.58–2.47)
0.98 (0.49–2.14)
1.27 (0.62–2.84)
Smoking
No
Ex-smoker
Yes
Reference
1.31 (1.01–1.70)
2.32 (1.72–3.14)
Alcohol, units
≤7
≤8–≤14
≤15–≤21
≤22
Reference
0.91 (0.67–1.22)
0.92 (0.57–1.42)
1.03 (0.64–1.61)
Physical activity
Hard training and competitive sports several 
times a week
Training, heavy garden work, or similar ≥4 
times a week
Walking, cycling, light garden work, or 
similar ≥4 times a week
Reading, watching tv, or other sedentary 
work
Reference
1.69 (0.91-3.35)
1.96 (1.09-3.81)
3.15 (1.69-6.26)
Comorbidity
CCI score 0
CCI score 1–2
CCI score ≥3
Reference
1.04 (0.82–1.32)
1.17 (0.82–1.63)
Duration of MPN disease
<1 year
1–4 years
≥5 years
Reference
1.37 (0.87–2.24)
1.49 (0.96–2.42)
Financial difficulties (EORTC QLQ-C30)
Not at all
A little
Quite a bit
Very much
Reference
3.71 (2.74–5.00)
4.43 (2.79–7.00)
6.45 (3.65–11.54)
Health-related quality of life
Symptom burden (MPN-SAF TSS)
Score 0–7
Score 8–17
Score 18–30
Score 31–100
Reference
4.68 (2.60–9.07)
12.46 (7.14–23.60)
36.24 (21.04–68.07)
OR (95% CI)*
Sexual problems (MPN-SAF)
Score 0
Score 1–2
Score 3–7
Score 8–10
Reference
2.14 (1.44–3.16)
3.02 (2.20–4.17)
5.92 (4.31–8.19)
Fatigue (EORTC QLQ-C30)
Score 0–11.11
Score 11.12–33.33
Score 33.34–55.56
Score 55.57–100
Reference
4.05 (2.46–7.04)
15.13 (9.19–26.33)
29.41 (17.82–51.34)
Physical functioning (EORTC QLQ-C30)
Score 93.34–100
Score 80.01–93.33
Score 60.01–80.00
Score 0–60.00
Reference
1.72 (1.19–2.50)
3.76 (2.66–5.36)
7.20 (5.07–10.34)
Role functioning (EORTC QLQ-C30)
Score 100
Score 83.34–99.99
Score 66.68–83.33
Score 0–66.67
Reference
2.29 (1.48–3.50)
4.40 (3.15–6.17)
9.64 (7.04–13.34)
Emotional functioning (EORTC QLQ-C30)
Score 100
Score 83.34–99.99
Score 66.68–83.33
Score 0–66.67
Reference
3.20 (1.56–7.05)
21.25 (11.52-43.86)
144.89 (78.31–300.30)
Cognitive functioning (EORTC QLQ-C30)
Score 100
Score 83.34–99.99
Score 66.68–83.33
Score 0–66.67
Reference
2.91 (2.00–4.28)
8.42 (5.75–12.52)
18.39 (12.66–27.18)
Social functioning (EORTC QLQ-C30)
Score 100
Score 66.68–99.99
Score 0–66.67
Reference
4.43 (3.35–5.89)
13.43 (9.78–18.56)
Global health/quality of life (EORTC  
QLQ-C30)
Score 83.33–100
Score 66.67–83.32
Score 50.00–66.66
Score 0–49.99
Reference
3.74 (2.48–5.70)
9.59 (6.58–14.24)
22.73 (15.54–33.93)
Notes: Symptom burden, sexual problems, fatigue, functioning, and global health/
quality-of-life scores presented as quartiles; social functioning score divided into 
three levels, because half the population had a score of 100. *Adjusted for age, sex, 
and comorbidity.
Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; CI, 
confidence interval; EORTC QLQ-C30, European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30; MPN, myeloproliferative 
neoplasm; MPN-SAF: Myeloproliferative Neoplasm Symptom Assessment Form; 
MPN-SAF TSS, Myeloproliferative Neoplasm Symptom Assessment Form Total 
Symptom Score; OR, odds ratio.
Table 3 (Continued)
(Continued)
Higher age might at least partly explain the lowest 
prevalence of psychological distress among MF participants 
compared to participants with other MPN subtypes.
In the American study by McFarland et al, the prevalence 
of anxiety was 31% in MPN patients, higher than in the 
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Table 4 Factors associated with depression
OR (95% CI)*
Demographics
Age, years
<50
50–75
>75
Reference
0.44 (0.29–0.68)
0.41 (0.26–0.66)
Sex
Male
Female
Reference
0.88 (0.67–1.15)
Education
Basic school
Upper secondary/vocational school
Higher education
Reference
0.75 (0.52–1.09)
0.72 (0.47–1.10)
Lifestyle
BMI
<18.5
≤18.5–<25.0
≤25.0–<30.0
≥30.0
Reference
0.99 (0.44–2.64)
1.04 (0.45–2.80)
1.11 (0.47–3.08)
Smoking
No
Yes
Ex-smoker
Reference
1.98 (1.37–2.86)
1.23 (0.89–1.71)
Alcohol, units
≤7
≤8–≤14
≤15–≤21
≤22
Reference
0.65 (0.43–0.95)
0.42 (0.19–0.80)
1.16 (0.69–1.87)
Physical activity
Hard training and competitive sports 
several times a week
Training, heavy garden work, or similar ≥4 
times a week
Walking, cycling, light garden work or 
similar ≥4 times a week
Reading, watching tv, or other sedentary 
work
Reference
0.91 (0.45–1.94)
1.10 (0.58–2.27)
3.05 (1.58–6.43)
Comorbidity  
CCI score 0
CCI score 1–2
CCI score ≥3
Reference
1.39 (1.03–1.86)
1.55 (1.02–2.31)
Duration of MPN disease
<1 year
1–4 years
≥5 years
Reference
0.82 (0.51–1.38)
0.75 (0.47–1.25)
Financial difficulties (EORTC QLQ-C30)
Not at all
A little
Quite a bit
Very much
Reference
3.02 (2.10–4.29)
5.06 (3.06–8.20)
7.78 (4.31–13.89)
Health-related quality of life
Symptom burden (MPN-SAF TSS)
Score 0–7
Score 8–17
Score 18–30
Score 31–100
Reference
13.77 (4.09–85.75)
40.40 (12.55–247.21)
113.70 (35.89–691.24)
OR (95% CI)*
Sexual problems (MPN-SAF)
Score 0
Score 1–2
Score 3–7
Score 8–10
Reference
1.10 (0.62–1.89)
2.47 (1.67–3.68)
4.73 (3.25–6.96)
Fatigue (EORTC QLQ-C30)
Score 0–11.11
Score 11.12–33.33
Score 33.34–55.56
Score 55.57–100
Reference
12.09 (3.64–74.85)
63.31 (19.65–387.48)
170.69 (53.36–1042.0)
Physical functioning (EORTC QLQ-C30)
Score 93.34–100
Score 80.01–93.33
Score 60.01–80.00
Score 0–60.00
Reference
5.20 (2.88–9.82)
10.50 (6.00–19.44)
25.07 (14.42–46.34)
Role functioning (EORTC QLQ-C30)
Score 100
Score 83.34–99.99
Score 66.68–83.33
Score 0–66.67
Reference
3.57 (1.88–6.73)
6.56 (3.96–11.19)
20.10 (12.73–33.17)
Emotional functioning (EORTC QLQ-C30)
Score 100
Score 83.34–99.99
Score 66.68–83.33
Score 0–66.67
Reference
2.55 (1.05–6.79)
10.71 (5.11–26.18)
74.49 (36.96–177.92)
Cognitive functioning (EORTC QLQ-C30)
Score 100
Score 83.34–99.99
Score 66.68–83.33
Score 0–66.67
Reference
2.04 (1.13–3.83)
7.95 (4.60–14.43)
34.19 (20.66–60.11)
Social functioning (EORTC QLQ-C30)
Score 100
Score 66.68–99.99
Score 0–66.67
Reference
6.44 (4.23–10.05)
28.08 (18.50–43.81)
Global health/quality of life (EORTC 
QLQ-C30)
Score 83.33–100
Score 66.67–83.32
Score 50.00–66.66
Score 0–49.99
Reference
14.18 (5.49–48.28)
50.09 (20.58–165.43)
131.92 (54.67–433.74)
Notes: Symptom burden, sexual problems, fatigue, functioning, and global health/
quality of life scores presented as quartiles; social functioning score divided into 
three levels, because half the population had a score >100. *Adjusted for age, sex, 
and comorbidity.
Abbreviations: BMI, body mass index; CCI, Charlson Comorbidity Index; CI, 
confidence interval; EORTC QLQ-C30, European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire Core 30; MPN, myeloproliferative 
neoplasm; MPN-SAF: Myeloproliferative Neoplasm Symptom Assessment Form; 
MPN-SAF TSS, Myeloproliferative Neoplasm Symptom Assessment Form Total 
Symptom Score; OR, odds ratio.
Table 4 (Continued)
(Continued)
MPNhealthSurvey,12 and the prevalence of depression was 
found to be 13%, fairly similar to the MPNhealthSurvey. In 
the international survey by Scherber et al, the prevalence of 
depression was as high as 23% in MPN patients.6 The preva-
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lence of anxiety and depression in the MPNhealthSurvey was 
found to be quite similar to those found in a meta-analytically 
pooled prevalence of 18% for anxiety and 12% for depres-
sion found in long-term cancer survivors.30 The prevalence of 
depression in the MPNhealthSurvey was also roughly equal 
with that found in a meta-analysis of cancer patients from 
hematological and oncological settings,31 with 16% preva-
lence for depression, but only 10% for anxiety. Among these 
previous studies, that by McFarland et al12 and certain studies 
presented in the meta-analysis by Mitchell et al30,31 used the 
HADS, like the MPNhealthSurvey, whereas in the study by 
Scherber et al6 and several of the studies in the meta-analysis, 
other tools were used to estimate the prevalence of anxiety and 
depression. These different approaches to measuring anxiety 
and depression make comparing results among these studies 
difficult. Furthermore, because MPN patients are chronic 
cancer patients, their disease trajectory differs from that of 
cancer patients with a fulminant trajectory, cancer patients 
who can potentially be cured, and long-term survivors. It is 
nevertheless interesting to compare anxiety and depression 
among MPN participants in the MPNhealthSurvey with 
patients included in the meta-analyses, particularly in terms 
of how burdened MPN participants were from anxiety and 
depression compared to cancer patients with other disease 
trajectories. Among respondents to the MPNhealthSurvey, 
prevalence of anxiety, in particular, but also that of depres-
sion, was closer to prevalence rates found in long-term cancer 
survivors than those found in patients with a hematological 
or oncological disease currently in a hospital setting. Poten-
tially, this is because the uncertainty involved with the risk 
of disease relapse among long-term cancer survivors and 
the risk of disease progression in MPN patients, as well as 
the burden of sequelae in long-term cancer survivors and 
the burden of symptoms in MPN patients, are comparable 
in terms of mental strain. In a large Swedish study of the 
general population of 6,659 individuals by Djukanovic et al, 
prevalence of anxiety was 11%, whereas that of depression 
was 10%.32 The mean age of the general population in the 
Swedish study was higher than was that of the population in 
the MPNhealthSurvey (71.2 vs 68.9 years), and the youngest 
participant in the Swedish study was 65 years, whereas in the 
MPNhealthSurvey some participants were in their 20s. In the 
MPNhealthSurvey, higher age was associated with lower odds 
of anxiety and depression. A comparison of the prevalence 
of psychological distress in the general population in the 
Swedish study and the population in the MPNhealthSurvey 
suggests that notably more MPN patients suffer from anxiety 
compared to the general population, whereas slightly more 
individuals in the general population suffer from depres-
sion compared to MPN patients. However, the difference in 
mean age and age span in the populations might mean that 
the actual difference in psychological distress is somewhat 
different than what we find by comparing the prevalence of 
psychological distress in these two populations.
In the studies by McFarland et al12 and Scherber et al,6 
MPN subtype was not associated significantly with anxiety 
or depression. The findings of the MPNhealthSurvey support 
these findings. Similarly, Scherber et al found younger age, 
higher fatigue and total symptom burden, and reduced QoL 
were associated with depression,6 which is supported by the 
results of this study.
The strengths and limitations of the MPNhealthSurvey 
have been outlined in detail in a previously published article 
on its survey design and the characteristics of respondents 
and nonrespondents.16 They are summarized in the follow-
ing. There were major strengths regarding selection bias in 
our survey. First, MPN patients invited to participate in this 
survey had equal access to treatment for their hematologi-
cal disease, because all Danish MPN patients attend public 
hospitals offering cost-free treatment of MPN financed by 
taxes. In contrast, however, costs related to medical treat-
ment of psychological distress are partly paid by patients, 
possibly with attendant inequalities. Second, the survey was 
nationwide and population-based. The unique NPR and 
CPR register in Denmark made this survey design possible. 
Third, patients could participate in the survey by returning 
a questionnaire booklet with a prepaid return envelope 
or completing the survey online. These elements of the 
survey design might have reduced selection bias notably 
and ensured a large population for investigation. Another 
strength of this survey is that it used the validated HADS 
questionnaire, which measures anxiety and depression, and 
involved a comprehensive investigation of the associated 
factors of anxiety and depression using questionnaires and 
additional questions covering lifestyle, as well as comor-
bidity information from the NPR. To our knowledge, no 
previous survey has reported a similar design or a similar 
large number of participants. Finally, another strength was 
that we considered MPN-U patients in the investigation of 
anxiety and depression, which has not previously been done.
There are limitations of this survey. First, we assume that 
some misclassified diagnoses are registered in the NPR. This 
would have an impact on the number of participants in each 
MPN subgroup by subclassification and on participants’ 
comorbidities. Second, the survey was cross-sectional. A 
prospective survey of psychological distress in Philadelphia-
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negative MPN patients might have provided more reliable 
estimations of the prevalence of anxiety and depression and 
explanations for some of the associations, eg, whether fatigue 
causes psychological distress or vice versa and whether 
limited physical activity causes psychological distress or 
vice versa. Third, anxiety and depression were assessed 
using a self-report questionnaire, rather than by a diagnos-
tic interview, which is the gold standard for assessment of 
psychological distress.33 The HADS has been shown to have 
assessment capability inferior to a diagnostic interview. Fur-
thermore, patients with symptoms might be overrepresented 
among respondents compared to patients with no symptoms, 
because the former might be more interested in research 
related to their condition. On the other hand, the 120 questions 
within the survey might have been overwhelming for some 
patients, such as those with psychological distress and high 
symptom burden, and the elderly, which might explain some 
nonresponses. In addition, sexual problems were assessed 
using one single item from the MPN-SAF questionnaire, 
and translation of the MPN-SAF into Danish was performed 
according to international recommendations; however, no 
validation of the questionnaire translated into Danish was 
performed. Finally, we did not adjust for living arrangements 
in our analysis of the factors associated with psychological 
distress, and this variable might have influenced the results. 
We had information on marital status from the CPR register, 
but since relatively many couples in Denmark are cohabitant 
without being married, we found adjustment for marital status 
insufficient in these analyses.
The reason patients diagnosed with MPN between March 
31, 2013 and September 4, 2013 were not included in this 
survey was that we could not ethically justify contacting these 
newly diagnosed patients by postal mail regarding a survey 
of this type. Likewise, we could not ethically justify sending 
more than one reminder to these cancer patients. 
Nevertheless, the findings do allow us to make some 
suggestions for clinical practice and research. First, we sug-
gest that outpatient hematological clinics be alert to anxiety 
and depression among MPN patients. We believe there may 
be unmet needs in the detection of and treatment and sup-
port in handling anxiety and depression in a considerable 
number of MPN patients.34 Regular assessment of potential 
psychological distress via diagnostic interview would be 
optimal. However, this might not be possible, due to the 
limited psychologist resources in hematological outpatient 
clinics. As such, an alternative would be regular screening for 
anxiety and depression, eg, using the HADS to help identify 
signs of anxiety and  depression early in the psychological 
distress trajectory.  Second, we suggest that medical staff 
pay attention not only to signs of anxiety and depression but 
also their related factors to better detect and help vulnerable 
patients. An unhealthy lifestyle, reduced functioning, and a 
high symptom burden were all associated with psychological 
distress. Therefore, lifestyle interventions, rehabilitation, and 
symptom reduction might be essential for the prevention and 
at least as a part of treatment of anxiety and depression in 
MPN patients. Future research could fruitfully explore the 
utility of such interventions.
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